Aquablation在门诊手术中心的首个美国试点研究:临床结局与经济可行性
本研究评估了在美国门诊手术中心(ASC)开展Aquablation治疗良性前列腺增生(BPH)的临床结局与经济可行性。101例中重度下尿路症状(LUTS)患者术后3个月IPSS从22.0降至9.2,Qmax从10.6升至18.3 mL/sec,Clavien-Dindo≥III级并发症率为1%。经济分析显示ASC Aquablation贡献边际高于TURP、Greenlight和HoLEP,且较医院Aquablation平均每例节省1800美元。
要点
- Aquablation可在无过夜能力的ASC安全开展,全部患者当日出院。
- 术后3个月IPSS、Qmax及残余尿均显著改善,并发症率低。
- ASC Aquablation经济性优于传统切除术式,每例节省1800美元。
核心结论
- Aquablation可在ASC安全有效开展,临床结局与关键试验一致且经济性良好。
- 支持将门诊Aquablation作为BPH的成本意识型高价值治疗选择。
研究设计与样本
- 单中心队列研究,纳入101例中重度LUTS继发BPH男性,在医生拥有的无过夜能力ASC接受Aquablation,随访3个月。
- 另分析169例的报销数据以评估经济影响和贡献边际。
主要发现
- 全部101例当日出院,平均恢复室停留1.5小时,无转院或30天再入院。
- IPSS从基线均值22.0改善至3个月9.2。
- Qmax从10.6增至18.3 mL/sec,残余尿从161.0降至40.1 mL。
- Clavien-Dindo≥III级并发症率为1%。
- ASC Aquablation贡献边际显著高于TURP、Greenlight和HoLEP,较医院Aquablation平均每例节省1800美元。
临床怎么用
- 在ASC开展Aquablation可作为BPH的可行治疗选项,需确保无过夜能力下的安全流程。
- 经济分析提示ASC Aquablation对医疗系统具有成本节约优势。
局限性
- 单中心设计,随访仅3个月,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical outcomes and economic feasibility of Aquablation therapy for benign prostatic hyperplasia (BPH) performed in a U.S.-based ambulatory surgery center (ASC) setting. METHODS: This single-center cohort study included 101 men with moderate to severe lower urinary tract symptoms (LUTS) secondary to BPH who underwent Aquablation at a physician-owned ASC with no overnight admission capabilities. Patients were followed for 3 months postoperatively. Clinical outcomes, including symptom scores, uroflow parameters, sexual health metrics, and complications were assessed. Additionally, reimbursement data from 169 cases were analyzed to evaluate economic impact and contribution margins relative to traditional resective BPH procedures. RESULTS: All 101 patients were successfully discharged the same day, with a mean recovery room stay of 1.5 hours and no transfers or 30-day readmissions. IPSS scores improved from a baseline mean of 22.0 to 9.2 at 3 months. Qmax increased from 10.6 to 18.3mL/sec, and post-void residual decreased from 161.0 to 40.1 mL. The overall Clavien-Dindo grade ≥III complication rate was 1%. Economic analysis showed ASC Aquablation had significantly higher contribution margins compared to TURP, Greenlight, and HoLEP, and saved the healthcare system an average of $1800 per case compared to hospital-based Aquablation. CONCLUSION: Aquablation can be safely and effectively performed in an ASC setting with clinical outcomes that mirror the pivotal trials and a favorable economic profile. These findings support the feasibility of outpatient Aquablation as a cost-conscious, high-value treatment option for BPH.
引用
- Marhamati S, Kangotra I, Perez D, et al. First-in-US Pilot Study of Aquablation in Ambulatory Surgery Centers: Clinical Outcomes and Economic Feasibility. Urology. 2025. PMID: 41015303. doi:10.1016/j.urology.2025.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。